GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

donidalorsen   Click here for help

GtoPdb Ligand ID: 13610

Synonyms: Dawnzera® | IONIS-PKK-LRx | ISIS 721744 | ISIS-721744 | ISIS721744
Approved drug
donidalorsen is an approved drug
Compound class: Nucleic acid
Comment: The INN record for donidalorsen describes it as a prekallikrein synthesis reducer. It is an antisense oligonucleotide (ASO) from Ionis Pharmaceuticals (formerly IONIS-PKK-LRx or ISIS 721744) that targets prekallikrein mRNA. The ASO is conjugated to a three N-acetylgalactosamine (GalNAc) moieties to improve delivery to the site of prekallikrein production in hepatocytes [2]. By silencing prekallikrein donidalorsen down-modulates the defective C1 inhibitor-prekallikrein-bradykinin pathway which promotes vasodilation, vascular permeability and dangerous episodes of tissue swelling that are characteristic of hereditary angioedema.

Full sequence as provided in the agent's INN record is: all-P-ambo-5'-O-(28-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis{[3-({6-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]hex-yl}amino)-3-oxopropoxy]methyl}-1-hydroxy-1,10,14,21-tetraoxo-2,18-dioxa-9,15,22-triaza-1λ5 -phosphaoctacosan-1-yl)-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')- 2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'→5')-2'-O-(2-methoxyethyl)adenylyl-(3'→5')-2'-O-(2- methoxyethyl)-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl- (3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)adenylyl-(3'→5')-2'-O-(2- methoxyethyl)adenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P- thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)adenosine, but we have been unable to resolve this to a SMILES or HELM notation.
No information available.
Summary of Clinical Use Click here for help
IONIS-PKK-LRx was progressed to clinical evaluation to determine efficacy as a treatment for hereditary angioedema (HAE). It was FDA approved for this indication on 21st August 2025.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04307381 An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema Phase 2 Interventional Ionis Pharmaceuticals, Inc. 1
NCT04030598 A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema Phase 2 Interventional Ionis Pharmaceuticals, Inc.
NCT05139810 OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE) Phase 3 Interventional Ionis Pharmaceuticals, Inc. 2-3